Research and Markets


Printer Friendly

Printed from http://www.researchandmarkets.com/reports/577433


Animal Pharms Top 20: 2006 Edition


Description: Animal Pharm’s Top 20 is recognised throughout the animal health and nutrition industry as a key source of information and analysis on the 20 largest companies in the sector. Invest in this report to keep informed of the performance of your potential competitors, collaborators or customers.

Key Findings:
- Global sales of animal health and nutrition products totalled almost US$21.7 billion in 2005. That figure was around 7% higher than the year-earlier total of US$20.3 billion.
- Sales of veterinary pharmaceuticals and biologicals for use in small animals alone are now worth almost US$6 billion, a figure equivalent to more than 27% of the entire market.
- The 13% increase in revenues reported by Pfizer Animal Health in 2005 saw the company consolidate its position at the head of the global sales league, with a gap of more than US$200 million between it and second-placed Merial.
- Merial appears set to leapfrog Pfizer in 2006, regaining the leadership position it held prior to Pfizer’s acquisition of Pharmacia Corp in 2003.
- The acquisition of Adisseo by the China National Chemical Corp (CNCC), announced late in 2005 and completed in 2006, is among the most significant M&A developments reported recently in the industry.
- Despite SPAH’s recent problems in the US market, most recent results indicate that the worst may finally be behind the company, with US sales up sharply on year-earlier figures in the first half of 2006.
- Merial’s Frontline sales fell back by 11% on year-earlier figures in the third quarter of 2005. That was followed by a 31% gain in the final quarter, however, and further strong growth through the first half of 2006.

This report profiles the businesses of 20 leading companies that generate aggregate annual revenues equivalent in value to more than three-quarters of global animal health and nutrition product sales. Each profile analyses the background of the company concerned, and examines in detail the size, structure and recent performance of its animal health business. Information on individual company strategies, R&D pipelines and future performance prospects is also provided.

Information sources used to compile the report include the Informa newsletter, Animal Pharm World Animal Health and Nutrition News; a range of other trade press sources; corporate web sites, annual reports, presentations and other publications; and contacts within the industry or at individual companies.

The structure of the world animal health and nutrition products market is discussed in an introductory section, which includes tabulated company sales rankings for 2005 and ranking forecasts for 2006. It also includes an analysis of profit levels being generated by leading companies in the sector. Data included in the latter section indicates that pre-tax margins towards the top end of the industry currently average a little over 18%. Among the companies that publish earnings data for their animal health businesses, Eli Lillys Elanco subsidiary is the most profitable, posting an operating margin of just under 25% in 2005.

Aggregate sales generated by the 20 market leaders rose by a little over 7% to almost US$16.3 billion in 2005. Early indications are that a similar increase will be posted in 2006, but individual performances will again vary widely. Perhaps most significantly, Merial appears to be on track to displace Pfizer at the head of the industry sales league during 2006, having booked a sales gain of more than 16% in the first half of the year. Merial is one of six companies expected to report a double-digit increase in revenues this year. Two of the industrys three biggest businesses - Pfizer and Intervet - will post low single-figure gains, however, and aggregate sales of the 20 market leaders are forecast to rise by a little over 7% once again.


Contents: CHAPTER 1 INTRODUCTION 13
1.1 The world market for animal health and nutrition products 13
1.1.1 Market shares by region 13
1.1.2 Market shares by product category 14
1.1.3 Market shares by species 15
1.2 The animal health and nutrition products industry 16
1.2.1 Leading companies in the animal health and nutrition sector 17
1.2.1.1 Market leaders in 2005 17
1.2.1.2 Market leaders in 2006 18
1.2.2 Industry profit levels 20
1.3 Currencies and exchange rates used in this report 21

CHAPTER 2 ADISSEO 23
2.1 Company background 23
2.2 Animal nutrition sales 23
2.2.1 2004 performance 24
2.2.2 2005 performance 24
2.2.3 Interim 2006 performance 24
2.3 Geography of the business 25
2.3.1 Europe, Middle East, Africa and CIS 25
2.3.2 Asia/Pacific 26
2.3.3 Latin America 26
2.3.4 North America 27
2.4 Product portfolio 27
2.4.1 Methionine 27
2.4.2 Vitamins 28
2.4.3 Enzymes 29
2.5 R&D 29
2.6 Strategy 30
2.7 Prospects 31

CHAPTER 3 ALPHARMA 33
3.1 Company background 33
3.2 Animal health sales and operating profit 34
3.2.1 2004 performance 35
3.2.2 2005 performance 36
3.2.3 Interim 2006 performance 36
3.3 Geography of the business 37
3.3.1 US 37
3.3.2 International markets 38
3.4 Product portfolio 39
3.4.1 Antibiotics 39
3.4.2 Anticoccidials 40
3.4.3 Antibacterials 40
3.4.4 Other products 41
3.5 R&D 41
3.6 Strategy 42
3.7 Prospects 43

CHAPTER 4 BASF 45
4.1 Company background 45
4.2 Animal nutrition sales 46
4.2.1 2004 performance 47
4.2.2 2005 performance 47
4.2.3 Interim 2006 performance 48
4.3 Geography of the business 48
4.3.1 Europe 49
4.3.2 Americas 49
4.3.3 Asia/Pacific 50
4.4 Product portfolio 51
4.4.1 Vitamins 51
4.4.2 Amino acids 51
4.4.3 Carotenoids 52
4.4.4 Enzymes 52
4.4.5 Other products 53
4.5 R&D 53
4.6 Strategy 54
4.7 Prospects 55

CHAPTER 5 BAYER 57
5.1 Company background 57
5.2 Animal health sales and operating income 58
5.2.1 2004 performance 59
5.2.2 2005 performance 60
5.2.3 Interim 2006 performance 60
5.3 Geography of the business 61
5.3.1 North America 61
5.3.2 Europe 62
5.3.3 Asia/Pacific 63
5.3.4 Latin America, Africa & Middle East 63
5.4 Product portfolio 64
5.4.1 Antiparasitics 64
5.4.2 Antimicrobials 67
5.4.3 Other products 67
5.5 R&D 68
5.6 Strategy 70
5.7 Prospects 70

CHAPTER 6 BOEHRINGER INGELHEIM 73
6.1 Company background 73
6.2 Animal health sales 74
6.2.1 2004 performance 74
6.2.2 2005 performance 75
6.2.3 Interim 2006 performance 75
6.3 Geography of the business 75
6.3.1 Europe 76
6.3.2 North America 76
6.3.3 Other markets 77
6.4 Product portfolio 78
6.4.1 Pharmaceuticals 78
6.4.2 Biologicals 80
6.4.3 Other products 81
6.5 R&D 82
6.6 Strategy 83
6.7 Prospects 84

CHAPTER 7 CEVA 85
7.1 Company background 85
7.2 Animal health sales and earnings 85
7.2.1 2004 performance 86
7.2.2 2005 performance 87
7.2.3 Interim 2006 performance 87
7.3 Geography of the business 88
7.3.1 Europe 89
7.3.2 International markets 90
7.4 Product portfolio 91
7.4.1 Companion animal and behavioral products 92
7.4.2 Reproductive controls 93
7.4.3 Anti-infectives 93
7.4.4 Vaccines 94
7.4.5 Others 94
7.5 R&D 95
7.6 Strategy 95
7.7 Prospects 96

CHAPTER 8 DAINIPPON SUMITOMO PHARMA 99
8.1 Company background 99
8.2 Animal health sales and operating profit 100
8.2.1 Fiscal 2005 performance 101
8.2.2 Fiscal 2006 performance 101
8.3 Geography of the business 102
8.4 Product portfolio 102
8.4.1 Companion animal products 103
8.4.2 Food animal products 104
8.5 R&D 104
8.6 Strategy 105
8.7 Prospects 105

CHAPTER 9 DEGUSSA 107
9.1 Company background 107
9.2 Feed additive sales 108
9.2.1 2004 performance 109
9.2.2 2005 performance 109
9.2.3 Interim 2006 performance 110
9.3 Geography of the business 110
9.4 Product portfolio 112
9.4.1 Methionine 112
9.4.2 Other amino acids 113
9.5 R&D 114
9.6 Strategy 114
9.7 Prospects 115

CHAPTER 10 DSM 117
10.1 Company background 117
10.2 Animal nutrition sales 118
10.2.1 2004 performance 118
10.2.2 2005 performance 119
10.2.3 Interim 2006 performance 119
10.3 Geography of the business 119
10.4 Product portfolio 120
10.4.1 Vitamins 121
10.4.2 Carotenoids 121
10.4.3 Feed enzymes 122
10.4.4 Other products 123
10.5 R&D 123
10.6 Strategy 124
10.7 Prospects 125

CHAPTER 11 ELANCO 127
11.1 Company background 127
11.2 Animal health sales and operating income 128
11.2.1 2004 performance 128
11.2.2 2005 performance 129
11.2.3 Interim 2006 performance 129
11.3 Geography of the business 130
11.3.1 US 130
11.3.2 International markets 131
11.4 Product portfolio 132
11.4.1 Tylosin 132
11.4.2 Tilmicosin 132
11.4.3 Monensin 133
11.4.4 Avilamycin 134
11.4.5 Ractopamine 134
11.4.6 Other products 134
11.5 R&D 135
11.6 Strategy 136
11.7 Prospects 137

CHAPTER 12 FORT DODGE 139
12.1 Company background 139
12.2 Animal health sales and operating profit 140
12.2.1 2004 performance 141
12.2.2 2005 performance 141
12.2.3 Interim 2006 performance 141
12.3 Geography of the business 142
12.3.1 US 142
12.3.2 International markets 143
12.4 Product portfolio 144
12.4.1 Biologicals 145
12.4.2 Antiparasitics 147
12.4.3 Other pharmaceuticals 149
12.5 R&D 149
12.6 Strategy 151
12.7 Prospects 151

CHAPTER 13 IDEXX 153
13.1 Company background 153
13.2 Sales and income 154
13.2.1 2004 performance 154
13.2.2 2005 performance 155
13.2.3 Interim 2006 performance 155
13.3 Geography of the business 156
13.3.1 North America 156
13.3.2 International markets 157
13.4 Product portfolio 158
13.4.1 Companion animal group 158
13.4.1.1 Immunoassays 159
13.4.1.2 Veterinary instrument systems 159
13.4.1.3 Reference laboratory and consulting services 160
13.4.1.4 Information management and radiography 160
13.4.1.5 Veterinary pharmaceuticals 160
13.4.2 Water products and services 161
13.4.3 Food diagnostics group 161
13.5 R&D 162
13.6 Strategy 164
13.7 Prospects 165

CHAPTER 14 INTERVET 167
14.1 Company background 167
14.2 Animal health sales and operating profit 168
14.2.1 2004 performance 168
14.2.2 2005 performance 169
14.2.3 Interim 2006 performance 169
14.3 Geography of the business 170
14.3.1 Europe 171
14.3.2 Americas 172
14.3.3 Other markets 172
14.4 Product portfolio 173
14.4.1 Biologicals 174
14.4.2 Antiparasitics 177
14.4.3 Anti-infectives 177
14.4.4 Other products 178
14.5 R&D 179
14.6 Strategy 181
14.7 Prospects 182

CHAPTER 15 MERIAL 183
15.1 Company background 183
15.2 Animal health sales 184
15.2.1 2004 performance 184
15.2.2 2005 performance 185
15.2.3 Interim 2006 performance 185
15.3 Geography of the business 185
15.polio 188
15.4.1 Avermectins 188
15.4.2 Fipronil 190
15.4.3 Biologicals 192
15.4.4 Other products 194
15.5 R&D 194
15.6 Strategy 196
15.7 Prospects 197

CHAPTER 16 NOVARTIS 199
16.1 Company background 199
16.2 Animal health sales and operating profit 200
16.2.1 2004 performance 201
16.2.2 2005 performance 201
16.2.3 Interim 2006 performance 202
16.3 Geography of the business 202
16.3.1 North America 202
16.3.2 Europe 203
16.3.3 Other markets 204
16.4 Product portfolio 204
16.4.1 Antiparasitics 205
16.4.2 Anti-infectives 207
16.4.3 Other pharmaceuticals 208
16.4.4 Vaccines 209
16.5 R&D 210
16.6 Strategy 211
16.7 Prospects 212

CHAPTER 17 PFIZER 215
17.1 Company background 215
17.2 Animal health sales and operating profit 216
17.2.1 2004 performance 217
17.2.2 2005 performance 217
17.2.3 Interim 2006 performance 218
17.3 Geography of the business 218
17.3.1 US 219
17.3.2 International markets 220
17.4 Product portfolio 221
17.4.1 Anti-infectives 221
17.4.2 Antiparasitics 224
17.4.3 Vaccines 225
17.4.4 Other pharmaceuticals 228
17.5 R&D 228
17.6 Strategy 230
17.7 Prospects 231

CHAPTER 18 PHIBRO 233
18.1 Company background 233
18.2 Animal health & nutrition sales and operating profit 234
18.2.1 Fiscal 2004 performance 235
18.2.2 Fiscal 2005 performance 235
18.2.3 Interim fiscal 2006 performance 236
18.3 Geography of the business 236
18.4 Product portfolio 237
18.4.1 Phibro Animal Health 238
18.4.2 Koffolk 239
18.4.3 Prince Agri Products 239
18.5 R&D 240
18.6 Strategy 240
18.7 Prospects 241

CHAPTER 19 SCHERING-PLOUGH 243
19.1 Company background 243
19.2 Animal health sales and earnings 244
19.2.1 2004 performance 245
19.2.2 2005 performance 246
19.2.3 Interim 2006 performance 246
19.3 Geography of the business 247
19.3.1 US 247
19.3.2 International markets 248
19.4 Product portfolio 249
19.4.1 Antiparasitics 249
19.4.2 Anti-infectives 250
19.4.3 Vaccines 251
19.4.4 Other products 253
19.5 R&D 254
19.6 Strategy 255
19.7 Prospects 256

CHAPTER 20 VETOQUINOL 259
20.1 Company background 259
20.2 Animal health sales 259
20.2.1 2004 performance 260
20.2.2 2005 performance 261
20.2.3 Interim 2006 performance 261
20.3 Geography of the business 261
20.3.1 Europe 262
20.3.2 North America 263
20.3.3 Other markets 263
20.4 Product portfolio 264
20.4.1 Anti-infectives 264
20.4.2 Other pharmaceuticals 265
20.4.3 Other products 266
20.5 R&D 267
20.6 Strategy 268
20.7 Prospects 269

CHAPTER 21 VIRBAC 271
21.1 Company background 271
21.2 Animal health sales and operating profit 272
21.2.1 2004 performance 272
21.2.2 2005 performance 273
21.2.3 Interim 2006 performance 273
21.3 Geography of the business 274
21.3.1 Europe 275
21.3.2 North America 275
21.3.3 Other markets 276
21.4 Product portfolio 277
21.4.1 Antiparasitics 277
21.4.2 Anti-infectives 278
21.4.3 Biologicals 279
21.4.4 Other products 280
21.5 R&D 280
21.6 Strategy 281
21.7 Prospects 282

LIST OF TABLES
Table 1.1 Geography of the world market, 2005 13
Table 1.2 World market structure by product category, 2005 14
Table 1.3 World market structure by species, 2005 15
Table 1.4 Top 20 rankings, 2005 17
Table 1.5 Top 20 ranking forecasts, 2006 19
Table 1.6 Leading animal health company earnings in 2005 20
Table 2.1 Adisseo animal nutrition sales, 2001-2005 24
Table 2.2 Adisseo sales by region, 2005 25
Table 3.1 Alpharmas revenues by division, 2005 34
Table 3.2 Alpharma animal health sales, 2001-2005 34
Table 3.3 Alpharma animal health earnings and margins, 2001-2005 35
Table 3.4 Alpharma first half sales, 2005 and 2006 37
Table 3.5 Alpharmas major product sales, 2005 39
Table 4.1 BASF sales by operating segment, 2005 46
Table 4.2 BASF animal nutrition sales, 2001-2005 46
Table 5.1 Bayer sales by operating segment, 2005 58
Table 5.2 Bayer animal health sales, 2001-2005 59
Table 5.3 Bayer animal health earnings and margins, 2001-2005 59
Table 5.4 Bayers first half sales, 2005-2006 60
Table 5.5 Bayer animal health sales by region, 2005 61
Table 5.6 Bayer animal health sales by species segment, 2004 and 2005 64
Table 5.7 Bayers imidacloprid sales, 2001-2005 65
Table 5.8 Bayer animal health research spending, 2001-2005 68
Table 5.9 Bayers late-stage development pipeline 69
Table 6.1 Boehringer Ingelheim sales by business area, 2005 74
Table 6.2 BIV sales, 2001-2004 74
Table 6.3 BIV sales by region, 2005 76
Table 6.4 Sales of key BIV pharmaceutical brands 79
Table 6.5 BIV spending on R&D, 2001-2005 82
Table 7.1 Ceva animal health sales, 2001-2005 86
Table 7.2 Ceva earnings and operating margins, 2001-2005 86
Table 7.3 Cevas first half sales, 2005 and 2006 88
Table 7.4 Ceva animal health sales by region, 2005 1 89
Table 7.5 Ceva animal health sales by species, 2005 1 92
Table 8.1 DSP sales by business segment, fiscal 2006 1 100
Table 8.2 DSP Animal Science sales, fiscal 2002-2006 1 101
Table 8.3 DSP Animal Science sales by product sector, fiscal 2006 1 102
Table 9.1 Degussa sales by operating segment, 2005 108
Table 9.2 Degussa feed additive sales, 2001-2005 109
Table 10.1 DSM sales by operating segment, 2005 118
Table 11.1 Elancos animal health sales, 2001-2005 128
Table 11.2 Elancos operating income and margin, 2001-2005 128
Table 11.3 Elancos interim 2006 sales performance 129
Table 11.4 Elancos US/international sales split, 2001-2005 130
Table 12.1 Wyeth sales by operating segment, 2005 140
Table 12.2 Fort Dodge animal health sales, 2001-2005 140
Table 12.3 Fort Dodge operating income and margins, 2001-2005 140
Table 12.4 Fort Dodge first half sales, 2005-2006 142
Table 12.5 Fort Dodge US/international sales split, 2001-2005 142
Table 12.6 Fort Dodge sales by species, 2005 145
Table 13.1 Idexx sales, 2001-2005 154
Table 13.2 Idexx earnings and operating margin, 2001-2005 154
Table 13.3 Idexx first half sales, 2005 and 2006 156
Table 13.4 Idexx sales by region, 2005 156
Table 13.5 Idexx sales by operating segment, 2005 158
Table 13.6 Companion animal group revenues by business area 159
Table 13.7 Idexx spending on R&D, 2001-2005 163
Table 14.1 Akzo Nobel sales by operating segment, 2005 168
Table 14.2 Intervet animal health sales, 2001-2005 168
Table 14.3 Intervets first half sales, 2005 and 2006 170
Table 14.4 Intervet sales by region, 2005 171
Table 14.5 Intervet sales by product segment, 2005 173
Table 15.1 Merial animal health sales, 2001-2005 184
Table 15.2 Merial first half animal health sales, 2005 and 2006 185
Table 15.3 Merial sales by product category, 2005 188
Table 15.4 Merials avermectin revenues, 2001-2005 189
Table 15.5 Leading formulations in the Merial ivermectin range 190
Table 15.6 Fipronil sales, 2001-2005 191
Table 16.1 Novartis sales by operating segment, 2005 200
Table 16.2 Novartis animal health sales, 2001-2005 200
Table 16.3 Novartis animal health sales by region, 2005 202
Table 16.4 Novartis animal health sales by product segment, 2005 205
Table 17.1 Pfizer sales by operating segment, 2005 216
Table 17.2 Pfizer animal health sales, 2001-2005 216
Table 17.3 Pfizer animal health operating profit and margins, 2001-2005 217
Table 17.4 Pfizer first half animal health sales, 2005 and 2006 218
Table 17.5 Pfizers US/international sales split, 2004 and 2005 219
Table 17.6 Pfizer animal health sales by species segment, 2004 and 2005 221
Table 17.7 Recent additions to the Pfizer anti-infectives range 222
Table 18.1 PAHC sales by operating segment, fiscal 2005 1 234
Table 18.2 PAHC animal health and nutrition sales, fiscal 2001-2005 1 235
Table 18.3 PAHC interim animal health sales, fiscal 2006 1 236
Table 18.4 PAHC animal health and nutrition sales by product category, fiscal 2005 1 237
Table 19.1 Schering-Plough sales by business sector, 2005 244
Table 19.2 SPAH sales, 2001-2005 244
Table 19.3 SPAH earnings and divisional margins, 2001-2005 245
Table 19.4 SPAH first half sales, 2005 and 2006 246
Table 19.5 SPAHs US/international sales split, 2004 and 2005 247
Table 20.1 Vétoquinol sales, 2001-2005 260
Table 20.2 Vétoquinol sales by region, 2005 261
Table 20.3 Vétoquinols key acquisitions 262
Table 20.4 Vétoquinol sales by product category, 2005 264
Table 21.1 Virbac animal health sales, 2001-2005 272
Table 21.2 Virbac first half sales, 2005 and 2006 274
Table 21.3 Virbac sales by region, 2005 274
Table 21.4 Virbac sales by product segment, 2005 277

nutrition sales, 2001-2005 46
Table 5.1 Bayer sales by operating segment, 2005 58
Table 5.2 Bayer animal health sales, 2001-2005 59
Table 5.3 Bayer animal health earnings and margins, 2001-2005 59
Table 5.4 Bayers first half sales, 2005-2006 60
Table 5.5 Bayer animal health sales by region, 2005 61
Table 5.6 Bayer animal health sales by species segment, 2004 and 2005 64
Table 5.7 Bayers imidacloprid sales, 2001-2005 65
Table 5.8 Bayer animal health research spending, 2001-2005 68
Table 5.9 Bayers late-stage development pipeline 69
Table 6.1 Boehringer Ingelheim sales by business area, 2005 74
Table 6.2 BIV sales, 2001-2004 74
Table 6.3 BIV sales by region, 2005 76
Table 6.4 Sales of key BIV pharmaceutical brands 79
Table 6.5 BIV spending on R&D, 2001-2005 82
Table 7.1 Ceva animal health sales, 2001-2005 86
Table 7.2 Ceva earnings and operating margins, 2001-2005 86
Table 7.3 Cevas first half sales, 2005 and 2006 88
Table 7.4 Ceva animal health sales by region, 2005 1 89
Table 7.5 Ceva animal health sales by species, 2005 1 92
Table 8.1 DSP sales by business segment, fiscal 2006 1 100
Table 8.2 DSP Animal Science sales, fiscal 2002-2006 1 101
Table 8.3 DSP Animal Science sales by product sector, fiscal 2006 1 102
Table 9.1 Degussa sales by operating segment, 2005 108
Table 9.2 Degussa feed additive sales, 2001-2005 109
Table 10.1 DSM sales by operating segment, 2005 118
Table 11.1 Elancos animal health sales, 2001-2005 128
Table 11.2 Elancos operating income and margin, 2001-2005 128
Table 11.3 Elancos interim 2006 sales performance 129
Table 11.4 Elancos US/international sales split, 2001-2005 130
List of Tables Animal Pharm’s Top 20: 2006 Edition
© Informa UK Ltd, October 2006 10 www.animalpharmreports.com
Photocopying & distribution of this document is illegal
Table 12.1 Wyeth sales by operating segment, 2005 140
Table 12.2 Fort Dodge animal health sales, 2001-2005 140
Table 12.3 Fort Dodge operating income and margins, 2001-2005 140
Table 12.4 Fort Dodge first half sales, 2005-2006 142
Table 12.5 Fort Dodge US/international sales split, 2001-2005 142
Table 12.6 Fort Dodge sales by species, 2005 145
Table 13.1 Idexx sales, 2001-2005 154
Table 13.2 Idexx earnings and operating margin, 2001-2005 154
Table 13.3 Idexx first half sales, 2005 and 2006 156
Table 13.4 Idexx sales by region, 2005 156
Table 13.5 Idexx sales by operating segment, 2005 158
Table 13.6 Companion animal group revenues by business area 159
Table 13.7 Idexx spending on R&D, 2001-2005 163
Table 14.1 Akzo Nobel sales by operating segment, 2005 168
Table 14.2 Intervet animal health sales, 2001-2005 168
Table 14.3 Intervets first half sales, 2005 and 2006 170
Table 14.4 Intervet sales by region, 2005 171
Table 14.5 Intervet sales by product segment, 2005 173
Table 15.1 Merial animal health sales, 2001-2005 184
Table 15.2 Merial first half animal health sales, 2005 and 2006 185
Table 15.3 Merial sales by product category, 2005 188
Table 15.4 Merials avermectin revenues, 2001-2005 189
Table 15.5 Leading formulations in the Merial ivermectin range 190
Table 15.6 Fipronil sales, 2001-2005 191
Table 16.1 Novartis sales by operating segment, 2005 200
Table 16.2 Novartis animal health sales, 2001-2005 200
Table 16.3 Novartis animal health sales by region, 2005 202
Table 16.4 Novartis animal health sales by product segment, 2005 205
Table 17.1 Pfizer sales by operating segment, 2005 216
Table 17.2 Pfizer animal health sales, 2001-2005 216
Table 17.3 Pfizer animal health operating profit and margins, 2001-2005 217
Table 17.4 Pfizer first half animal health sales, 2005 and 2006 218
Table 17.5 Pfizers US/international sales split, 2004 and 2005 219
Table 17.6 Pfizer animal health sales by species segment, 2004 and 2005 221
Table 17.7 Recent additions to the Pfizer anti-infectives range 222
Table 18.1 PAHC sales by operating segment, fiscal 2005 1 234
Table 18.2 PAHC animal health and nutrition sales, fiscal 2001-2005 1 235
Table 18.3 PAHC interim animal health sales, fiscal 2006 1 236
Table 18.4 PAHC animal health and nutrition sales by product category,
fiscal 2005 1 237
Table 19.1 Schering-Plough sales by business sector, 2005 244
Table 19.2 SPAH sales, 2001-2005 244
Table 19.3 SPAH earnings and divisional margins, 2001-2005 245
Table 19.4 SPAH first half sales, 2005 and 2006 246
Table 19.5 SPAHs US/international sales split, 2004 and 2005 247
Table 20.1 Vétoquinol sales, 2001-2005 260
Table 20.2 Vétoquinol sales by region, 2005 261
Table 20.3 Vétoquinols key acquisitions 262
List of Tables Animal Pharm’s Top 20: 2006 Edition
© Informa UK Ltd, October 2006 11 www.animalpharmreports.com
Photocopying & distribution of this document is illegal
Table 20.4 Vétoquinol sales by product category, 2005 264
Table 21.1 Virbac animal health sales, 2001-2005 272
Table 21.2 Virbac first half sales, 2005 and 2006 274
Table 21.3 Virbac sales by region, 2005 274
Table 21.4 Virbac sales by product segment, 2005 277


Companies Mentioned - Adisseo - Alpharma - BASF - Bayer - Boehringer Ingelheim - Ceva - Dainippon Sumitomo Pharma - Degussa - Dsm - Elanco - Fort Dodge - Idexx - Intervet - Merial


Ordering: Order Online - visit http://www.researchandmarkets.com/reports/577433

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


Research and Markets Page 1 of 2
Printed 27/11/2009 23:45:02
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net

Order information
Please verify that the product information is correct and select the format you require.
Product Name:
Animal Pharms Top 20: 2006 Edition
Web Address:
http://www.researchandmarkets.com/reports/577433
Office Code:
OC8HJNPOUMUXU

Report formats
Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User €890.00



Contact information
Please enter all the information below in BLOCK CAPITALS.

First Name:   Last Name:  
Email Address:
Job Title:
Organisation:
Address:
City:
Postal/Zip Code:
Country:
Phone Number:
Fax Number:


Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Research and Markets Page 2 of 2
Printed 27/11/2009 23:45:02

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

 Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder's Name:
Cardholder's Signature:
Expiry Date: /
Card Number:
CVV Security Code:
Issue Date: /   (Diners Club only)


 Pay by Check:
Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


 Pay by Wire Transfer:
Please transfer funds to:

Account number: 83313083
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:


Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)